Abstract
High SERPINE1 expression is a common event in head and neck squamous cell carcinoma (HNSCC); however, whether it plays a role in determining clinical outcome remains still unknown. We studied SERPINE1 as a prognostic marker in two HNSCC patient cohorts. In a retrospective study (n = 80), high expression of SERPINE1 was associated with poor progression-free (p = 0.022) and cancer-specific (p = 0.040) survival. In a prospective study (n = 190), high SERPINE1 expression was associated with poor local recurrence-free (p = 0.022), progression-free (p = 0.002) and cancer-specific (p = 0.006) survival. SERPINE1 expression was identified as an independent risk factor for progression-free survival in patients treated with chemo-radiotherapy or radiotherapy (p = 0.043). In both patient cohorts, high SERPINE1 expression increased the risk of metastasis spread (p = 0.045; p = 0.029). The association between SERPINE1 expression and survival was confirmed using the HNSCC cohort included in The Cancer Genome Atlas project (n = 507). Once again, patients showing high expression had a poorer survival (p < 0.001). SERPINE1 over-expression in HNSCC cells reduced cell proliferation and enhanced migration. It also protected cells from cisplatin-induced apoptosis, which was accompanied by PI3K/AKT pathway activation. Downregulation of SERPINE1 expression had the opposite effect. We propose SERPINE1 expression as a prognostic marker that could be used to stratify HNSCC patients according to their risk of recurrence.
Highlights
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer in incidence worldwide [1, 2]
We identified SERPINE1 expression as a poor prognostic marker in head and neck squamous cell carcinoma
We used a third patient cohort of HNSCC (n = 507) included in The Cancer Genome Atlas (TCGA) database to support the association between SERPINE1 expression and patient survival
Summary
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer in incidence worldwide [1, 2]. The development of new predictive biomarkers could help to classify this heterogeneous group of tumors and improve treatment decision-making [5]. SERPINE1 (PAI-1) is the main regulator of the PA system, and it is involved in signal transduction, tumor growth, invasion and metastasis [9]. It is the main inhibitor of the plasminogen activators tPA and uPA. SERPINE1 expression has been validated as a marker for therapy decision making in patients with node-negative breast cancer [13, 14]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.